Glenmark Pharmaceuticals Limited - Company Profile

It is a pharma public limited company based in Mumbai, Maharashtra, India, established in 1977.
1977 Mumbai, Maharashtra, India Active
Last Updated:
Access Report
About Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Limited, a active public limited company, was established on 18 November 1977 in Mumbai, Maharashtra, India. Engaging in drug formulation & development within the manufacturing sector, it holds CIN: L24299MH1977PLC019982. Registered under ROC Roc Mumbai. it is listed on BSE: 532296 and NSE: GLENMARK. It has an authorized capital of ₹277.00 Cr and a paid-up capital of ₹28.22 Cr.

Formerly known as Glenmark Pharmaceuticals Private Limited. It upholds a compliant status. In 2024, it reported revenue of ₹9,059.14 Cr and a net worth of ₹22,970.62 Cr. Employing 13,458 professional, Its leadership includes Glenn Mario Saldanha (Managing Director), Dipankar Bhattacharjee (Director), Blanche Saldanha Elizabeth (Director). Past directors included Marshall Joseph Mendonza, Mahadevan Gopal Krishnan, Natvarlal Bhimbhai Desai. It holds ₹890.00 Cr open charges and ₹1,040.00 Cr settled loans. Its latest AGM occurred on 26 September 2025, with the balance sheet filed on 31 March 2025. It is based at B-2Mahalaxmi Chambers22 Bhulabhai Desai Road Mahalaxmi, Mumbai, Maharashtra, 400026.

Company Details
  • Email
    **********
  • Telephone

    +91-XXXXXXXXXX

  • Website
    **********
  • Social Media
    **********
  • Apps
    **********

Company Details

  • CIN/LLPIN

    L24299MH1977PLC019982

  • Registration Number

    019982

  • Incorporation Date

    18 November 1977

  • Authorized Capital

    ₹277.00 Cr

  • Paid-Up Capital

    ₹28.22 Cr

  • ROC Code

    Roc Mumbai

  • Listing Status

    Listed (BSE: 532296, NSE: GLENMARK)

  • Company Status

    Active

Key Metrics
  • Authorised Capital ₹ 277.00 Cr
  • Paid Up Capital ₹ 28.22 Cr
  • Company Age 48 Year, 2 Months
  • Last Filing with ROC 31 Mar 2025
  • Open Charges ₹ 890.00 Cr
  • Satisfied Charges ₹ 1,040.00 Cr
  • Revenue Growth **** -1.60%
  • Profit Growth **** 327.48%
  • Ebitda **** -15.69%
  • Net Worth 28.49%
  • Total Assets **** 11.50%
Company report

Glenmark Pharmaceuticals Limited

Company Report FY 2025-2026

Comprehensive Company Insights

Explore comprehensive insights into Glenmark Pharmaceuticals Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.

Access Report Banner Element
Who are the key members and board of directors at Glenmark Pharmaceuticals Limited?
Current Directors
Name Designation Appointment Date Status
Glenn Mario Saldanha Managing Director 12 Oct 1998 Current
Dipankar Bhattacharjee Director 14 Aug 2020 Current
Blanche Saldanha Elizabeth Director 14 Aug 2009 Current
Sona Saira Ramasastry Director 01 Apr 2019 Current
Anurag Mantri Cfo 27 May 2025 Current
Pradeep Kumar Sinha Director 14 Feb 2025 Current
Past Directors
Name Designation Cessation Status
Pramod Abcsdd Company Secretary 07 May 2013 Past
Pramod Abcsdd Director 29 Jan 2010 Past
Pramod Abcsdd Director 01 Jun 2015 Past
Pramod Abcsdd Additional Director 29 Sep 2020 Past
Pramod Abcsdd Additional Director 25 Sep 2009 Past
Pramod Abcsdd Whole-Time Director 10 May 2011 Past

Discover detailed profiles of directors and KMP - Unlock leadership insights today!

Financial Performance of Glenmark Pharmaceuticals.

Glenmark Pharmaceuticals Limited, for the financial year ended 2024, experienced Minor drop in revenue, with a 1.6% decrease. The company also saw a substantial improvement in profitability, with a 327.48% increase in profit. The company's net worth Soared by an impressive increase of 28.49%.

Glenmark Pharmaceuticals revenue growth over time
Glenmark Pharmaceuticals profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors
Emtek
Feb, 2021 Amount Post-IPO - Grab Valuation

investors
Signite Partners
Jan, 2021 Amount Post-IPO - Grab Valuation

investors
Hana Financial Group , GGV Capital
Feb, 2021 Amount Post-IPO - Grab Valuation

investors
Signite Partners
  • Key Matrics
  • Balance Sheet
  • Profit and Loss
  • Cash Flow
  • Ratios
Metrics
(FY 2023) YOY Growth
(FY 2022) (FY 2021) (FY 2020) (FY 2019)
Total Revenue
********
 -1.60%
*******
*******
*******
*******
Revenue from Operations
*******
 -4.01%
*******
*******
*******
*******
Total Assets
*******
 11.50%
*******
*******
*******
*******
Profit or Loss
*******
 327.48%
*******
*******
*******
*******
Net Worth
*******
 28.49%
*******
*******
*******
*******
EBITDA
*******
 -15.69%
*******
*******
*******
*******

Discover detailed financial data and - Unlock financial today!

What is the Ownership and Shareholding Structure of Glenmark Pharmaceuticals?

In 2024, Glenmark Pharmaceuticals had a promoter holding of 46.65% and a public holding of 53.36%. The company had 1 Subsidiary. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.

Shareholding Pattern (FY 2024)
shareholding
  • Promoters: 92.83%
  • Public: 4.10%
  • Others: 3.07%
Shareholding Pattern over the Year
FY (2024) FY (2023) FY (2022) FY (2021) FY (2020)
Promoters 92.83 94.62 94.55 94.55 94.55
Public 4.10 3.89 3.95 3.96 3.98
Others 3.07 1.49 1.50 1.49 1.47

Reveal ownership structures and financial performance - Get instant access now!

Charges (Loans)
Open Charges

₹8,900,000,000.00

Satisfied Charges

₹10,400,000,000.00

Charges Breakdown by Lending Institutions
  • Bank Of India : 890.00 Cr
Latest Charge Details
Date Lender Amount Status
21 May 1985 Bank Of India ₹890.00 Cr Open
29 Jul 2009 Bank Of India ₹60.00 Cr Satisfied
18 Jun 2009 Axis Bank Limited ₹75.00 Cr Satisfied
16 Jan 2009 Central Bank Of India ₹150.00 Cr Satisfied
09 Jun 2008 Bank Of India ₹170.00 Cr Satisfied

Explore comprehensive loan charge details -

How Many Employees Work at Glenmark Pharmaceuticals?

Glenmark Pharmaceuticals has a workforce of 13458 employees as of Mar 08, 2025. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.

Employee Date Number of Employees
2020 78,000
2021 80,500
2022 83,200
2023 86,000
2024 89,500
2025 92,000
Deals i
Graph showing company valuation over time

Gain comprehensive insights into the Deals and Valuation data of Glenmark Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Glenmark Pharmaceuticals's trajectory.

Rating
Graph displaying rating trends over time

Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.

Alerts
Alert Indicator

Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.

Explore deal ratings and alerts - Get instant access now!

Latest Updates, News, and FAQs on Glenmark Pharmaceuticals
Recent Activity within the Organization
  • Annual General Meeting

    The activity Glenmark Pharmaceuticals Limited last Annual general meeting of members was held on 26 Sep 2025 as per latest MCA records. was completed.

  • Director Appointment

    Progress on Patricia Susan Andrews was appointed as a Director was appointed as a Director on 14 Aug 2025 & has been associated with this company since 5 months 28 days . was documented.

  • Director Appointment

    The activity Anurag Mantri was appointed as a CFO was appointed as a CFO on 27 May 2025 & has been associated with this company since 8 months 15 days . was completed.

  • Balance Sheet

    Progress on Glenmark Pharmaceuticals Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Mumbai. was documented.

  • Director Appointment

    Progress on Pradeep Kumar Sinha was appointed as a Director was appointed as a Director on 14 Feb 2025 & has been associated with this company since 11 months 26 days . was documented.

  • Director Appointment

    Vijayalakshmi Rajaram Iyer was appointed as a Director was appointed as a Director on 10 Feb 2023 & has been associated with this company since 3 years . was recorded as a recent event.

Explore recent activity and updates - View Recent Activity

Recent News, Updates & Announcement

Explore news and more updates - View Recent News

Frequently Asked Questions
What is the CIN of Glenmark Pharmaceuticals Limited?

The CIN of Glenmark Pharmaceuticals Limited is L24299MH1977PLC019982.

Where is Glenmark Pharmaceuticals Limited headquartered?

Glenmark Pharmaceuticals Limited is headquartered at B-2Mahalaxmi Chambers22 Bhulabhai Desai Road Mahalaxmi, Mumbai, Maharashtra, 400026.

When was Glenmark Pharmaceuticals Limited incorporated?

Glenmark Pharmaceuticals Limited was incorporated on 18 November 1977.

Who are the current directors of Glenmark Pharmaceuticals Limited?

The current directors of Glenmark Pharmaceuticals Limited are

What is the primary industry of Glenmark Pharmaceuticals Limited?

The primary industry of Glenmark Pharmaceuticals Limited is Manufacturing.

Is Glenmark Pharmaceuticals Limited a listed company?

Glenmark Pharmaceuticals Limited is listed. It is listed on BSE: 532296 and NSE: GLENMARK.

What is the capital structure of Glenmark Pharmaceuticals Limited?

The authorized capital of Glenmark Pharmaceuticals Limited is ₹277.00 Cr, and the paid-up capital is ₹28.22 Cr.

What is the compliance status of Glenmark Pharmaceuticals Limited?

The compliance status of Glenmark Pharmaceuticals Limited is Compliant.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available